Evolution of the Correa's cascade steps: A long-term endoscopic surveillance among non-ulcer dyspepsia and gastric ulcer after H. pylori eradication

Cheng, Hsiu–Chi; Yang, Yao-Jong; Yang, Haw‐Ching; Tsai, Yu-Ching; Chang, Wei‐Lun; Wu, Chung-Tai; Kuo, Hsin‐Yu; Yu, Yu‐Ting; Yang, Er-Hsiang; Cheng, Wei-Jen; Chen, Wei-Ying; Sheu, Bor–Shyang

doi:10.1016/j.jfma.2022.11.008

Cited by 7 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The process of carcinogenesis in GA consists of a process known as Correa's cascade in which precancerous gastric lesions, including gastritis, IM, and dysplasia in that order, progress into GA. 5 Secondary prevention of GC includes screening and treating precancerous lesions. Therefore, there is a need for biomarkers that can distinguish GC progression in its early stages.…”

Section: Discussionmentioning

confidence: 99%

“…These precancerous lesions were reported as non-atrophic gastritis, atrophic gastritis, intestinal metaplasia (IM), dysplasia, and invasive carcinoma respectively. 5 Previous studies showed that patients with precancerous lesions had a higher risk of GC. 6,7 Therefore, the prognosis of GC can be improved by early diagnosis of precancerous stages.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survivin as a potential biomarker for early diagnosis of the progression of precancerous lesions to gastric cancer

Mahmoudzadeh-Sagheb,

Panahi,

Jami

et al. 2023

Int J Biol Markers

View full text Add to dashboard Cite

Background Gastric cancer is a common cancer developed in a carcinogenesis process from precancerous lesions including chronic gastritis, intestinal metaplasia, and dysplasia. Survivin, an inhibitor-of-apoptosis protein, is associated with the initiation and progression of gastric cancer. The present study aimed to evaluate the immunohistochemical expression patterns of survivin and its relationship with early diagnosis of gastric cancer in Iranian patients. Methods In this retrospective case-control study, immunoexpression of survivin was investigated on sections obtained from formalin-fixed paraffin-embedded tissue blocks of 38 chronic gastritis, 32 intestinal metaplasia, 20 dysplasia, 28 gastric adenocarcinoma, and 22 controls. Results Survivin immunoexpression in chronic gastritis was higher than controls, but this difference was not statistically significant ( P > 0.05). However, survivin immunoexpression had a steady significant increase from control and chronic gastritis to intestinal metaplasia to dysplasia to gastric adenocarcinoma ( P < 0.05). Sensitivity, specificity, and area under the curve of survivin immunohistochemical test for the diagnosis of gastric cancer were 87.5%, 74.4%, and 0.85, respectively. Males had a significantly higher survivin expression than females ( P < 0.001). Also, survivin expression was significantly higher in older patients than in younger ones ( P < 0.001). Conclusion It seems that the steady increase in survivin expression from different precancerous lesions to gastric adenocarcinoma suggests that survivin can be used as a potential biomarker for the prevention and early diagnosis of gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Survivin as a potential biomarker for early diagnosis of the progression of precancerous lesions to gastric cancer

Mahmoudzadeh-Sagheb,

Panahi,

Jami

et al. 2023

Int J Biol Markers

View full text Add to dashboard Cite

show abstract

“…Возраст, стадии OLGA ≥ I и OLGIM ≥ I были независимыми фак-торами, коррелирующими со стойким высоким риском рака желудка. Эти данные могут быть полезны при планировании обзорной эндоскопии для больных c различными стадиями каскада Корреа [43].…”

Section: инвазивные методыunclassified

Modern aspects of Helicobacter pylori infection

Yakovleva

Смирнова

Korsunskiy

2023

RPJ

View full text Add to dashboard Cite

A systematic review of current data on the structure and functions of Helicobacter pylori (Hp), pathogenesis, diagnosis and treatment of Hp-infection is presented. The relevance of the topic of helicobacteriosis is due to the proven connection of this infection with chronic, widespread diseases of the digestive organs among the population. The review used materials from the databases including PubМed, Medline, EMBASE, Scopus, Google Scholar, RSCI. A systematic review based on studies with a high degree of evidence has shown significant progress in the diagnosis and treatment of Hp-infection in recent years in adults and children. Coordination of the scientific search for the regularities of the formation of Hp-associated forms of pathology, continuous improvement of diagnostic technologies and the search for new therapies, periodic well-organized international revisions of standard methods of Hp diagnosis and treatment contribute to the creation of effective methods of Hp eradication, preservation of the optimal composition of the microbiota of the gastrointestinal tract and prevention of antibiotic resistance. Of particular importance for the prevention of complications of Hp-infection are original diagnostic algorithms using specialized endoscopic and molecular technologies before and after Hp eradication with long-term follow-up and the determination of the leading factors correlating with a high risk of stomach cancer. The review indicates the emergence of potentially effective and promising areas for the diagnosis and treatment of Hp-infection, including genetic modification of the Hp genome to ensure its existence as a human symbiont and a significant reduction in its pathogenic properties. At the same time, sequencing of a new generation reveals mutations in Hp genes associated with its pathogenicity and antibiotic resistance, which contributes to the creation of new classes of drugs to increase the effectiveness of Hp eradication with a decrease in the proportion of antibiotics and an increase in pathogenetically significant inhibitors of its pathogenic factors for the prevention of side effects, a significant reduction in the empirical use of several antibiotics and increased compliance to treatment.

show abstract

“…Helicobacter pylori ( H. pylori ) is a major culprit of peptic ulcer disease and gastric cancer. H. pylori eradication can decrease the recurrence of peptic ulcer disease, halt the progression of precancerous conditions, and decrease the risk of gastric cancer 1–4 . New regimens have achieved eradication rates of ~84%–99% 5–11 .…”

Section: Introductionmentioning

confidence: 99%

“…H. pylori eradication can decrease the recurrence of peptic ulcer disease, halt the progression of precancerous conditions, and decrease the risk of gastric cancer. [1][2][3][4] New regimens have achieved eradication rates of ~84%-99%. [5][6][7][8][9][10][11] Sequential therapy has been shown to have a relatively high eradication rate and is currently the consensus recommendation for a first-line therapy for H. pylori infection.…”

Section: Introductionmentioning

confidence: 99%

The nonadherence and risk factors of eradication failure by sequential therapy as first‐line anti‐Helicobacter pylori treatment in real‐world clinical practice

Lee,

Wu,

Chang

et al. 2023

Helicobacter

Self Cite

View full text Add to dashboard Cite

BackgroundThe eradication rates of sequential therapy are high in clinical trials; however, the adherence for follow‐up or the patient population in a real‐world setting might be different from those in trails. This study investigates the effectiveness of sequential therapy in a real‐world setting and the factors that lead to treatment failure.Materials and MethodsIn this retrospective study, patients receiving sequential therapy as a first‐line anti‐Helicobacter pylori (H. pylori) treatment in a real‐world setting were reviewed. The age adjusted Charlson Comorbidity Index (age‐CCI) and baseline variety of medications were reviewed to determine factors correlated with nonadherence for post‐treatment testing and H. pylori eradication failure.ResultsA total of 1053 patients were reviewed. A total of 579 patients receiving sequential therapy were included in the analyses. Among them, 462 received post‐treatment testing and were placed into the follow‐up group. Thus, the post‐treatment testing rate was 79.8%. Stroke was an independent factor of nonadherence for post‐treatment testing. In the follow‐up group, the eradication failure rate was 8.2%. Female sex (odds ratio [OR] 2.41 [95% CI 1.16–5.03], p = 0.02) and age‐CCI ≥2 (OR 3.16 [1.05–9.48], p = 0.04) were independent factors of H. pylori eradication failure. The eradication failure rates were 14.4%, 7.8%, 7.1%, and 3.1% for the females with age‐CCI ≥2, females with age‐CCI <2, males with age‐CCI ≥2, and males with age‐CCI <2 subgroups, respectively (p = 0.027).ConclusionsIn a real‐world setting, the adherence rate of post‐treatment testing for sequential therapy as a first‐line anti‐H. pylori treatment was found to be suboptimal. Female sex and age‐CCI ≥2 were independent factors of eradication failure.

show abstract

Evolution of the Correa's cascade steps: A long-term endoscopic surveillance among non-ulcer dyspepsia and gastric ulcer after H. pylori eradication

Cited by 7 publications

References 39 publications

Survivin as a potential biomarker for early diagnosis of the progression of precancerous lesions to gastric cancer

Survivin as a potential biomarker for early diagnosis of the progression of precancerous lesions to gastric cancer

Modern aspects of Helicobacter pylori infection

The nonadherence and risk factors of eradication failure by sequential therapy as first‐line anti‐Helicobacter pylori treatment in real‐world clinical practice

Contact Info

Product

Resources

About